SG Americas Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

SG Americas Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,000	Closed	-$13K	–	3474
2023 Q4	$13K	Hold	15,000	–	–	﹤0.01%	3027
2023 Q3	$93K	Buy	15,000 +4,000	+36%	+$1.4M	﹤0.01%	2815
2023 Q2	$39K	Hold	11,000	–	–	﹤0.01%	2148
2023 Q1	$130K	Buy	+11,000	New	+$3.3M	﹤0.01%	2739
2022 Q4	–	Sell	-13,400	Closed	-$21K	–	3409
2022 Q3	$21K	Sell	13,400 -6,600	-33%	-$1.9M	﹤0.01%	3097
2022 Q2	$170K	Hold	20,000	–	–	﹤0.01%	2780
2022 Q1	$358K	Sell	20,000 -80,000	-80%	-$19M	﹤0.01%	2100
2021 Q4	$510K	Hold	100,000	–	–	﹤0.01%	2168
2021 Q3	$3.76M	Hold	100,000	–	–	0.02%	732
2021 Q2	$2.89M	Buy	+100,000	New	+$20.9M	0.01%	903
2020 Q2	–	Sell	-15,200	Closed	-$1K	–	3878
2020 Q1	$1K	Buy	+15,200	New	+$3.49M	﹤0.01%	3408
2017 Q1	–	Sell	-12,000	Closed	-$301K	–	3587
2016 Q4	$301K	Hold	12,000	–	–	﹤0.01%	2034
2016 Q3	$182K	Hold	12,000	–	–	﹤0.01%	2579
2016 Q2	$263K	Hold	12,000	–	–	﹤0.01%	1996
2016 Q1	$298K	Hold	12,000	–	–	﹤0.01%	1998
2015 Q4	$131K	Buy	+12,000	New	+$1.45M	﹤0.01%	2292
2015 Q3	–	Sell	-12,000	Closed	-$142K	–	2723
2015 Q2	$142K	Hold	12,000	–	–	﹤0.01%	2167
2015 Q1	$192K	Buy	+12,000	New	+$1.44M	﹤0.01%	1903

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SG Americas Securities's VRTX Position: Q1 2026 in Review

SG Americas Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q1 2026, selling an estimated $27.5M and leaving 56,982 shares worth $25.4M. The position accounts for 0.03% of the portfolio, ranked #459.

SG Americas Securities first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $52.5M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

SG Americas Securities held 56,982 shares of Vertex Pharmaceuticals worth $25.4M as of Q1 2026.
SG Americas Securities sold 58,917 Vertex Pharmaceuticals shares in Q1 2026, an estimated $27.5M.
Vertex Pharmaceuticals made up 0.03% of SG Americas Securities's portfolio in Q1 2026, its #459 holding.
SG Americas Securities first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
SG Americas Securities's Vertex Pharmaceuticals position peaked at $52.5M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.